GSK will pay $90 million to settle diabetes drug allegations

Share this article:
GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia. However, the company did not admit to “any wrongdoing or liability of any kind.” The states charged that GSK did not report some Avandia safety data. They also said the drug manufacturer violated consumer protection laws when it misrepresented heart attack risk with the drug, as well as the safety of its use, alone or in combination with other drugs.

Share this article:

More in Products

LINK Innovation Competition crowns Walalight best

The Walalight™ system, which simulates natural sunlight exposure and promotes regular circadian rhythms, won first place at the 2014 LINK Innovation Competition on Monday in Chicago.

Nestlé Professional MINOR adds low-sodium, gluten-free base

Nestlé Professional MINOR adds low-sodium, gluten-free base

MINOR's Low Sodium Gluten Free Base is available in chicken, beef and vegetable, Nestle Professional announced.

Larson Electronics debuts mobile power distribution system

Larson Electronics debuts mobile power distribution system

The Larson Electronics MDC-240-100MB-8X120 temporary power distribution system is now available for those who need to use power sources independently of a work area.